Company intelligence / Profile preview
Himalaya Therapeutics
Shanghai, Shanghai, Chinahimalayatherapeutics.com ↗
- Ownership
- Public · HMLA
- Development stage
- Phase 2
01
Overview
The company has multiple CAB antibodies in development, with two programs in Phase 2 clinical trials (Ozuriftamab vedotin and Mecbotamab vedotin) and two in Phase 1 (BA-3181 and BA3151). Their CAB technology creates antibodies that selectively bind to targets on tumor cells but not normal cells.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugates (ADCs)Bispecific T-cell Engagers (BiTEs)Bispecific antibodiesProbody drug conjugates
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
BioAtla (licensed CAB technology from BioAtla)
04
Financials
- Market cap
- $38.9K
- Total revenue
- $0
- Enterprise value
- $194.7K
Beyond the preview
Go deeper on Himalaya Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Himalaya Therapeutics.